Seres Therapeutics reports Q1 loss of $71.2M, VOWST approved, balance sheet strengthened with up to $250M facility

Seres Therapeutics, Inc.

2023-Q1 EPS reported -$0.57 revenue$-522,000

VOWST (fecal microbiota spores) FDA-approved for recurrent C. difficile; launch expected June 2023.
Q1 net loss $71.2M vs $56.6M YoY; R&D $44.0M incl. $16M commercial manufacturing; cash $106.5M.
Entered $250M debt facility with Oaktree; drew $110M (net ~$50M after retiring $53M debt).
Due $125M milestone from Nestlé Health Science upon VOWST approval; pro-forma cash ~$282M.
SER-155 Phase 1b Cohort 1 data: favorable tolerability, engraftment, reduced ESKAPE pathogen domination; Cohort 2 data mid-2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Seres Therapeutics, Inc. reported financial results for First Quarter 2023.

Period: First Quarter 2023
Result: reported results

Exact text from the filing

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2023 financial results and provided business updates.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-138954

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.